NCT01188278View on ClinicalTrials.gov

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

CompletedOBSERVATIONAL
Enrollment

173

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Leukemia, Myeloid, Chronic-Phase (CML-CP)
Interventions
DRUG

Imatinib

Drug being observed but not provided

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY